Precision BioSciences, Inc. (NASDAQ: DTIL) is a Healthcare company (Biotechnology) with a market capitalization of $197M. The Maz Rating grades it against the other companies in its sector.
Precision BioSciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.05, Precision BioSciences, Inc. trades at 4.4x sales and 3.7x book value. Over the last twelve months it generated about $45M of revenue and a net loss of $35M. It runs a gross margin of 98.7%, an operating margin of -80.3% and a net margin of -85.6%. It shows return on equity of -58.1%, return on invested capital of -31.8% and a free cash flow yield of -26.2%. On the balance sheet: a debt-to-equity ratio of 0.54 and a current ratio of 10.47. Over the past 52 weeks the share price ranged from $3.53 to $11.29, with a beta of 1.35.
Precision BioSciences, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 9 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Precision BioSciences, Inc. (DTIL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 12.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 43.4% / 30% · Interest income / Revenue 88100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 12.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 43.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 88100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 12.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 43.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 88100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 17.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 70.9% / 33.33% · Receivables / Avg Assets (4Q) 0.73% / 33.33% · Interest income / Revenue 88100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 20.0% / 33.33% · (Cash+ST Inv) / Total Assets 68.0% / 33.33% · (Cash+Recv) / Total Assets 68.0% / 33.33% · Interest income / Revenue 88100000.0% / 5% | Fail |
No. As of September 2026, Precision BioSciences, Inc. (DTIL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Precision BioSciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 88100000.0% of each dividend: Precision BioSciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.